Carvana stock soars after S&P 500 inclusion announcement
Investing.com - Cantor Fitzgerald initiated coverage on Sabra Healthcare REIT Inc. (NASDAQ:SBRA), a healthcare REIT with a market capitalization of $4.47 billion, with a Neutral rating and a $20.00 price target, representing approximately 6.2% upside from current levels. According to InvestingPro data, the stock is currently trading near its 52-week high, with a robust dividend yield of 6.44%.
The research firm based its valuation on a 2026 estimated AFFO multiple of 12.4x, which compares to a 19.0x average for the broader REIT industry, suggesting the stock trades at a discount to sector peers. InvestingPro analysis shows the company maintains strong financial health with an overall score of "GREAT" and has consistently paid dividends for 15 consecutive years.
Cantor Fitzgerald noted that Sabra has experienced renewed momentum in external growth, primarily in the Senior Housing/SHOP segment, though attractive skilled nursing facility deals are also beginning to materialize.
The firm highlighted Sabra’s strategic focus on significantly expanding its SHOP segment from 20% to 30% of its business portfolio in the foreseeable future.
While acknowledging that SBRA stock is relatively inexpensive compared to immediate peers, Cantor Fitzgerald indicated that a clear catalyst for relative outperformance remains to be determined.
In other recent news, Sabra Healthcare REIT Inc . reported its second-quarter 2025 earnings, surpassing market expectations. The company achieved an earnings per share (EPS) of $0.27, significantly higher than the forecasted $0.18, marking a 50% surprise. Revenue also exceeded predictions, reaching $189.15 million compared to the anticipated $181.53 million, a 4.2% surprise. Following these results, Citizens JMP increased its price target for Sabra Healthcare REIT to $22.00 from $20.00, maintaining a Market Outperform rating. This adjustment was influenced by the company’s Core FFO of $0.38 per share, which exceeded both Citizens and consensus expectations. Additionally, Truist Securities raised its price target for Sabra to $20.00 from $18.00, while keeping a Hold rating. Both firms noted improvements in Sabra’s financial metrics as a factor in their analyses. These developments highlight the company’s strong performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.